Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy

Fig. 2

Renal function tests: Serum creatinine and urine total protein throughout pembrolizumab and ipilimumab plus nivolumab therapy. Circles show serum creatinine while diamonds represent urine total protein at given time points. Upper limits of normal (ULN): Serum creatinine (ULN = 1.17 mg/l, indicated by dashed horizontal line) and urine total protein (ULN < = 120 mg/l). Black arrows indicate applications of ipilimumab/nivolumab, black cross indicates application of pembrolizumab

Back to article page